Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.

Tangherlini G, Kalinin DV, Schepmann D, Che T, Mykicki N, Ständer S, Loser K, Wünsch B.

J Med Chem. 2019 Jan 24;62(2):893-907. doi: 10.1021/acs.jmedchem.8b01609. Epub 2019 Jan 9.

PMID:
30543421
2.

Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?

Breuer J, Loser K, Mykicki N, Wiendl H, Schwab N.

J Neuroimmunol. 2019 Apr 15;329:1-8. doi: 10.1016/j.jneuroim.2018.05.006. Epub 2018 May 18. Review.

PMID:
29793727
3.

Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease.

Mykicki N, Herrmann AM, Schwab N, Deenen R, Sparwasser T, Limmer A, Wachsmuth L, Klotz L, Köhrer K, Faber C, Wiendl H, Luger TA, Meuth SG, Loser K.

Sci Transl Med. 2016 Oct 26;8(362):362ra146.

PMID:
27797962
4.

The tripeptide KdPT ameliorates ongoing psoriasis-like skin inflammation in murine and human skin.

Mykicki N, Klenner L, Baumann C, Auriemma M, Sternemann C, Soeberdt M, Elliott GR, Abels C, Luger TA, Loser K.

Exp Dermatol. 2017 Apr;26(4):328-334. doi: 10.1111/exd.13145. Epub 2016 Dec 9.

PMID:
27376341

Supplemental Content

Loading ...
Support Center